A young and restless market

Using the recent approval of GlaxoSmithKline plc's Requip ropinirole to treat restless legs syndrome as a blueprint, XenoPort Inc. hopes to follow suit with its own therapeutic candidate and then coattail on the pharma company's marketing efforts. Last week, XNPT's XP13512 met the primary endpoint in a Phase IIb trial in RLS.

RLS is an idiopathic disease characterized by an uncontrollable urge to move the legs that is either caused or accompanied by uncomfortable sensations in the lower extremities. The symptoms typically begin or worsen in the early evening and at night and often interfere with sleep. ...